Article Text

PDF
Doxycycline failure in lymphogranuloma venereum
  1. Frédéric Méchaï1,
  2. Bertille de Barbeyrac2,
  3. Olivier Aoun1,
  4. Audrey Mérens3,
  5. Patrick Imbert1,
  6. Christophe Rapp1
  1. 1Service des Maladies Infectieuses et Tropicales, Hôpital D'Instruction des Armées Bégin, Saint Mandé, France
  2. 2Centre National de Référence des Chlamydiae, Laboratoire de Bactériologie, Université Victor Segalen, Bordeaux, France
  3. 3Service de Biologie Clinique, Hôpital d'Instruction des Armées Bégin, Saint Mandé, France
  1. Correspondence to Dr Frédéric Méchaï, Service des Maladies Infectieuses et Tropicales, Hôpital d'Instruction des Armées Bégin, Saint Mandé 94160, France; mechaifrederic{at}wanadoo.fr

Abstract

Lymphogranuloma venereum (LGV) cases are currently re-emerging in the homosexual community, particularly in HIV-seropositive patients. The standard treatment for this infection, which is caused by Chlamydia trachomatis L1, L2 and L3 serotypes, is a 3-week doxycycline regimen. The case is reported of a male patient presenting with LGV, who was rapidly cured with moxifloxacin treatment after failure of extended treatment with cyclines. This fluoroquinolone is known to be highly active in vitro on the LGV pathogenic agent. Thus it may be a useful alternative when doxycycline treatment results in failure.

  • C trachomatis
  • doxycycline

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.